Boston Scientific, Medtronic, Abbott and J&J unveiled new data for their PFA devices in tandem with the Heart Rhythm ...

An attempted cavotricuspid isthmus ablation was unsuccessful due to abnormal ... Entrainment from the CTI was attempted but resulted in degeneration into atrial flutter. CTI ablation was initiated at ...

Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

single-shot PFA mapping and ablation catheter for treatment of paroxysmal atrial fibrillation (PAF). Results for Sphere-360 at one year, in a prospective, single-arm, multi-center trial performed ...

and posterior wall ablation (PWA), as well as the Farapoint PFA Catheter for cavotricuspid isthmus (CTI) ablation to treat typical atrial flutter (AFL). Subjects in the study were monitored using the ...

Boston Scientific has reported positive 12-month primary endpoint outcomes from the ADVANTAGE AF trial’s second phase, assessing the Farapulse pulsed field ablation (PFA) system and Farapoint ...

A significant proportion of patients undergoing atrial fibrillation (AF) ablation as part of the CABANA trial had a high probability of heart failure with preserved ejection fraction (HFpEF).

Boston Scientific (NYSE: BSX) today announced positive 12-month study results for its Farapulse pulsed field ablation (PFA) system.

With careful consideration of several factors, many patients can avoid an overnight stay, reducing costs without sacrificing ...

as well as the FARAPOINT PFA Catheter for cavotricuspid isthmus ablation in treating atrial flutter. The study reported 73.4% of patients were free from AF, atrial flutter, and atrial tachycardia ...

MARLBOROUGH, Mass. and SAN DIEGO, April 24, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of the ...